Recent 8-K filings for DXR

• January 26, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements ×2

  Daxor raises ~$8.1M in registered direct offering of 765,958 shares at $11.75/share

  Sold 765,958 shares at $11.75 per share for net proceeds of approx. $8,142,006 after fees.

• August 7, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  Daxor receives FDA 510(k) clearance for next-gen blood volume analyzer

  FDA 510(k) clearance (K251087) for patent-pending rapid, hand-held BVA device.

• March 25, 2024, 7:59 PM ET M&A materiality 0.75 positive item 8.01item 9.01

  Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics

  No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.

• January 2, 2024, 6:59 PM ET regulatory materiality 0.65 neutral item 8.01item 9.01

  Daxor submits next-gen BVA to FDA for 510(k)/CLIA-waiver; clearance expected H1 2024

  Submission via dual 510(k)/CLIA-waiver pathway to FDA for next-generation blood volume analyzer.

• May 26, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Daxor closes $4.0M public offering of 410,260 shares at $9.75/share

  Closed underwritten public offering of 410,260 shares at $9.75 per share, raising $4.0M gross.

Executive changes

Materiality & sentiment trend

Max materiality 0.75 · Median 0.43 · Most common event other_material

3 positive 0 negative 15 neutral

source · DXR on sec.gov